Carmen Martos

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Francesco Giusti

Joint Research Centre

Manola Bettio

Joint Research Centre

Giorgia Randi

Joint Research Centre

Nicholas Nicholson

Joint Research Centre

Luciana Neamţiu

Institute of Oncology Prof. Dr. Ion Chiricuta

R. Carvalho

Joint Research Centre

Nadya Dimitrova

Centre International de Recherche sur le Cancer

T Dyba

Joint Research Centre

Ghislaine Scélo

Observational & Pragmatic Research Institute

David Brewster

University of Edinburgh

Cooperative Institutions

Instituto de Salud Carlos III

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública

Universitat Autònoma de Barcelona

Centro de Investigación Biomédica en Red

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias

Centre International de Recherche sur le Cancer

University of Groningen

Fondazione IRCCS Istituto Nazionale dei Tumori

Institut Català d'Oncologia

Hospital Universitari Germans Trias i Pujol

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Candida biomarkers in patients with candidaemia and bacteraemia

Journal of Antimicrobial Chemotherapy (2015)

M. Carmen Martínez-Jiménez Patricia Muñóz Maricela Valerio Roberto Alonso Carmen Martos

Abstract Objectives Microbiological strategies are necessary to help clinicians discontinue empirical antifungal therapy in patients with suspected invasive candidiasis. Culture methods and biomarkers each show low sensitivity. We analysed the value of combining different biomarkers as a decision-making tool for discontinuing empirical antifungal treatment. Methods We studied stored serum samples from 31 patients with candidaemia (Candida albicans 40%, Candida tropicalis 20%, Candida parapsilosis 18%, Candida glabrata 12% and other 10%) and 50 patients with bacteraemia at Gregorio Marañón Hospital, Madrid, Spain. C. albicans germ tube antibody (CAGTA), mannan antigens (MN), antimannan antibodies (AMN) and (1→3)-β-d-glucan (BDG) were assayed using the manufacturer's and alternative cut-offs to improve the accuracy of the tests. Results The sensitivity of the biomarkers when used alone was low (58%−84%), but specificity was high (65.8%−92.0%). The best combinations were CAGTA and BDG using cut-offs of 1/80 and 80 pg/mL, respectively (sensitivity 96.8% and specificity 84%), and CAGTA and MN using cut-offs of 1/80 and 75 pg/mL, respectively (sensitivity 93.5% and specificity 86.0%). The sensitivity of both combinations was 100% for C. albicans, C. tropicalis and C. parapsilosis, but only combinations including BDG detected Candida krusei. The negative predictive values (NPVs) of both combinations were, respectively, 97.7% and 95.6% (prevalence of candidaemia, 23.6%). For a prevalence of candidaemia of 5% and 10%, the NPV reached 99.8% and 99.6%. Conclusions The combinations of CAGTA and BDG or CAGTA and MN had a very high NPV at the alternative cut-offs and could be used in antifungal stewardship programmes as a decision-making tool for discontinuing unnecessary empirical therapy in patients with suspected candidaemia.

Candida parapsilosis

Candida glabrata

Fungemia

Candida krusei

Germ tube

Invasive candidiasis

10.1093/jac/dkv090

Cite

Citations (59)

Comparing two approaches for estimating national incidence with regional cancer registration only

European Journal of Public Health (2018)

T Dyba Giorgia Randi Francesco Giusti Carmen Martos R. Carvalho

Results:The application of intersectionality on population-based studies including health reporting may guide the identification of which differences in health outcomes are explained by interlocking power relations.The study will yield the development of gender-sensitive categories to improve nonresponder analysis, multivariable data analysis methods and a model to structure and organize health reports empiricallybased and theoretically grounded in intersectionality. Conclusions:A toolkit of methods to improve identification and understanding of vulnerable populations is developed and shall be applied for a gender-sensitive health reporting.

Cancer Incidence

10.1093/eurpub/cky218.253

Cite

Citations (0)

Risk of second malignant neoplasms after childhood central nervous system malignant tumours: An international study

European Journal of Cancer (2008)

Milena Maule Ghislaine Scélo Guido Pastore Paul Brennan Kari Hemminki

Childhood Cancer

10.1016/j.ejca.2008.02.012

Cite

Citations (24)

COOPERATIVE TEAMWORK STUDENT ASSESSMENT IN COMMUNITY NURSING SUBJECT

ICERI2012 Proceedings (2012)

Luisa Ruano M.L. Ballestar Carmen Martos

Source

Cite

Citations (0)

The 2022 ENCR Recommendations on recording and reporting of urothelial tumours of the urinary tract

Frontiers in Oncology (2022)

Jaume Galcerán David Parada Michael Edén Rosario Tumino Anne Y. Warren

An updated European Network of Cancer registries (ENCR) Recommendations on Recording and Reporting of Urothelial Tumours of the Urinary Tract had been published in 2022. After the publication by the ENCR of the "Recommendations for coding bladder cancers" in 1995, knowledge about the biology and pathology of urinary tract tumors and their classification has varied and increased substantially. On the other hand, several studies have shown that cancer registries use different definitions, criteria for inclusion and coding of urothelial tumors. This great variability among registries affects not only the criteria for recording (registration, coding and classification) but also the criteria of reporting (counting in the statistics of incidence and survival) urinary tract tumors. This causes difficulties in the data comparability from different registries. Recording and reporting of urothelial tumors requires the application of standard criteria that must take into account the combination of the multiple aspects as the primary topography, the histological type, the grade, the extent of invasion, the multi-centricity, the progressions and the time interval between tumors. This led to the creation of a Working Group of the ENCR that developed these recommendations on the recording and reporting of urothelial tumors of the urinary tract. This article reports these recommendations and the rationale for each.

Urothelial cancer

Comparability

Urothelial Cell

10.3389/fonc.2022.1046239

Cite

Citations (4)

Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark

Birth Defects Research (2017)

Clara Cavero‐Carbonell Anne Vinkel Hansen Ma José Rabanque‐Hernández Carmen Martos Ester Garne

The objective was to study pregnancy outcomes between groups of Danish women, with pregnancy ending between 1998 and 2009, according to their exposure to montelukast.Cross-sectional observational study in Danish women, selecting live births and stillbirths (Birth Registry) and spontaneous abortions and induced terminations (Patient Registry). Montelukast exposure was obtained from the Prescription Registry (ATC code R03DC03). Exposure period was from 3 months before the last menstrual period until the end of the first trimester. Four groups were studied: (1) women with prescription for montelukast, (2) women with prescription for montelukast and other anti-asthmatic medications, (3) women with prescription for other anti-asthmatic medications, (4) women without prescription for any anti-asthmatic medications.A total of 754,300 singleton pregnancies (> 12 weeks) were identified: 401 pregnancies in group 1, 426 pregnancies in group 2, 24878 in group 3 and 728,595 in group 4. Risk of preterm birth, maternal preeclampsia and gestational diabetes was increased for pregnancies exposed to montelukast. No significant differences were found for the risk of major congenital anomalies (CA). Adjusted odds ratio for CA was 1.4 (95% CI 0.9-2.3) for the group 1 and 1.0 (95% CI 0.6-1.8) for group 2.Pregnant women with prescriptions for montelukast had a higher risk of preterm birth and maternal complications. These risks are known to be associated with maternal asthma, no increased risk of CA was found. Further analysis including more exposed pregnancies will be needed to determine the risk of specific CA. Birth Defects Research 109:452-459, 2017. © 2017 Wiley Periodicals, Inc.

10.1002/bdra.23621

Cite

Citations (35)

A case study using the European Cancer Information System web-application: Lung cancer incidence

European Journal of Public Health (2018)

Carmen Martos Francesco Giusti Giorgia Randi T Dyba R. Carvalho

10.1093/eurpub/cky212.190

Cite

Citations (1)

Joining forces for better cancer registration in Europe; ENCR Scientific meeting & General Assembly 5-7 October 2016, Baveno, italy

Manola Bettio Carvalho Raquel Giorgia Randi Francesco Giusti Dyba Tadeusz Artur

General assembly

10.2787/07824

Cite

Citations (0)

TNM Ed7 ontology

Carmen Martos Francesco Giusti

Source

Cite

Citations (0)

Cancer treatment data available in European cancer registries: Where are we and where are we going?

Frontiers in Oncology (2023)

Francesco Giusti Carmen Martos Annalisa Trama Manola Bettio Arantza Sanvisens

Population-based cancer registries are responsible for collecting incidence and survival data on all reportable neoplasms within a defined geographical area. During the last decades, the role of cancer registries has evolved beyond monitoring epidemiological indicators, as they are expanding their activities to studies on cancer aetiology, prevention, and quality of care. This expansion relies also on the collection of additional clinical data, such as stage at diagnosis and cancer treatment. While the collection of data on stage, according to international reference classification, is consolidated almost everywhere, data collection on treatment is still very heterogeneous in Europe. This article combines data from a literature review and conference proceedings together with data from 125 European cancer registries contributing to the 2015 ENCR-JRC data call to provide an overview of the status of using and reporting treatment data in population-based cancer registries. The literature review shows that there is an increase in published data on cancer treatment by population-based cancer registries over the years. In addition, the review indicates that treatment data are most often collected for breast cancer, the most frequent cancer in women in Europe, followed by colorectal, prostate and lung cancers, which are also more common. Treatment data are increasingly being reported by cancer registries, though further improvements are required to ensure their complete and harmonised collection. Sufficient financial and human resources are needed to collect and analyse treatment data. Clear registration guidelines are to be made available to increase the availability of real-world treatment data in a harmonised way across Europe.

Epidemiology of cancer

10.3389/fonc.2023.1109978

Cite

Citations (9)